Purified anti-PTEN Phospho (Ser380) Antibody, PTEN, A22005D,BioLegend,626452

ICC: This antibody is compatible with either PFA/Triton X-100 or PFA- Methanol fixation/permeabilization protocols. It is not suitable to use on methanol only fixation/permeabilization protocols.ICFC: This antibody is suitable to use in cells fixed with either Cyto-Fast™ Fix/Perm Buffer Set (Cat. No. 426803) or True-Phos™ Perm Buffer (Cat. No. 425401) systems. Not tested for use with the True-Nuclear™ Transcription Factor Buffer Set (Cat. No. 424401).

Host

Mouse

Reactivity

Human

Application

ICFC - Quality testedICC, IHC-P - Verified

Platform ID

BAB741034921

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePurified anti-PTEN Phospho (Ser380) Antibody, PTEN, A22005D
Cat. No.626452
HostMouse
RRIDAB_3083416 (BioLegend Cat. No. 626451)AB_3083416 (BioLegend Cat. No. 626452)
IsotypeMouse IgG1, κ
ReactivityHuman
ApplicationICFC - Quality testedICC, IHC-P - Verified
ClonalityMonoclonal
Clone NumberA22005D
Concentration0.5 mg/mL
TargetPTEN Phospho Ser380
ImmunogenSynthetic peptide from human PTEN phosphorylated at Serine 280
PurityThe antibody was purified by affinity chromatography.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.
Regulatory StatusResearch Use Only

Scientific Background

PTEN is a tumor suppressor gene which encodes a phosphatase that preferentially dephosphorylates phosphoinositide substrates and thereby modulates cell cycle progression and cell survival. PTEN is an important negative regulator of the PI3K/AKT/mTOR signaling pathway by dephosphorylating PIP3. PTEN is commonly mutated in human cancer, hence, loss of expression/function of PTEN due to mutations have been observed in prostate cancer, glioblastoma, endometrial, lung and breast cancers. Other non-cancerous clinical disorders associated with PTEN mutation are Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, and proteus-like syndrome. PTEN is phosphorylated at several residues and some lead to increase in activity while others lead to loss of function and degradation. Specifically, phosphorylation at serine 380 residue by casein kinase 2 (CK2), leads to degradation of PTEN in the proteasome.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.